TLSIW
TriSalus Life Sciences, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Jul 31 Short interest jumps 52.4% to 12.1K
- X Aug 14 Short interest jumps 70.4% to 20.5K
- X Sep 30 Short interest falls 47.7% to 9.4K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2025: 1 added (0 new), 1 trimmed or exited.
- TrendRANGE
12% below its 50-day average.
Who's buying
13F· Q3 2025| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | DOUBLED | $199.2K |
| TORONTO DOMINION BANK | TRIM | $8.5K |
| WOLVERINE ASSET MANAGEMENT LLC | TRIM | $10.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $14.0M |
| Next Q | — | — | — | $18.8M |
| Current FY | — | — | — | $53.1M |
| Next FY | — | — | — | $74.5M |
Short side
FINRA· Oct 15, 2026SecBot reports
2 filings · 0 bullish · 0 bearish · 2 neutral- NEUTRAL 8-KApr 29, 2026
TriSalus Life Sciences disclosed the planned retirement of Chief of Clinical Operations Jodi…
No immediate trading action warranted. Monitor for any successor announcement for the Chief of Clinical Operations role, which could signal organizational stability or disruption.
- NEUTRAL 8-KApr 7, 2026
TriSalus Life Sciences appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29…
Monitor upcoming earnings calls for discussion of R&D strategy changes under new CMO. Watch for insider trading activity related to Marshall's potential equity grants. Assess whether increased…
All TLSIW filing & press-release reports (2)
- 8-K reportApr 29, 2026
- 8-K reportApr 7, 2026